Latest news with #VEGFR-3
Hans India
05-08-2025
- Health
- Hans India
Indian scientists develop new approach for treatment of liver cirrhosis
New Delhi: A team of Indian scientists has found a new way to treat liver cirrhosis, by targeting the lymphatic vessels in the liver and intestine that fail in case of cirrhosis. Chronic liver disease can progress from mild disease to fibrosis to cirrhosis (also known as scarring). Cirrhosis is accompanied by the distortion of both blood and lymphatic vessels in the liver and the intestine. Patients with advanced cirrhosis often develop complications like fluid accumulation in the abdomen. A team of scientists from the Institute of Liver and Biliary Sciences (ILBS), New Delhi, and National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, focussed on improving the drainage capacity of lymphatic vessels in the liver and intestine by using nanocarriers filled with a powerful protein called VEGF-C. 'Vascular endothelial growth factor-C (VEGF-C) is a key pro-lymphangiogenic factor that activates lymphangiogenesis or new lymphatic vessel growth. It does this through binding to a cell membrane tyrosine kinase receptor, vascular endothelial growth factor receptor-3 (VEGFR-3), the activation of which is essential for the growth and development of new lymphatic vessels,' said the researchers. The team probed the therapeutic efficacy of VEGF-C in ameliorating gut lymphatic dysfunction and improving lymph drainage. Owing to the hydrophilicity, short half-life, and systemic side effects of VEGF-C, the team led by Dr Subham Banerjee from NIPER Guwahati first focused on the development of VEGF-C encapsulated reverse micelle-based nanocarriers, which specifically bind to VEGFR-3 homodimers. Next, the ILBS team, led by Dr Savneet Kaur, tested the developed VEGF-C nanocarriers extensively in animal models of advanced cirrhosis and portal hypertension. The developed molecule was delivered via the oral route to ensure its gut lymphatic vessel uptake in the animal models. The team showed that VEGF-C nanocarriers significantly increased mesenteric lymph drainage, which reduced ascites. Importantly, the treatment also led to an attenuation of the portal pressures, improved cytotoxic T-cell immunity in mesenteric lymph nodes, and reduced local and systemic bacterial load. The research, published in the JHEP Reports journal, is the first to highlight that therapeutic lymphangiogenesis with VEGF-C is a promising treatment for reconstructing the fragmented lymphatic network and restoring lymphatic function and drainage in advanced cirrhosis.
India.com
02-08-2025
- Health
- India.com
Breakthrough In Liver Cirrhosis Treatment: Indian Scientists Develop New Approach
New Delhi: A team of Indian scientists has found a new way to treat liver cirrhosis, by targeting the lymphatic vessels in the liver and intestine that fail in case of cirrhosis. Chronic liver disease can progress from mild disease to fibrosis to cirrhosis (also known as scarring). Cirrhosis is accompanied by the distortion of both blood and lymphatic vessels in the liver and the intestine. Patients with advanced cirrhosis often develop complications like fluid accumulation in the abdomen. A team of scientists from the Institute of Liver and Biliary Sciences (ILBS), New Delhi, and National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, focussed on improving the drainage capacity of lymphatic vessels in the liver and intestine by using nanocarriers filled with a powerful protein called VEGF-C. Pic Credits: IANS 'Vascular endothelial growth factor-C (VEGF-C) is a key pro-lymphangiogenic factor that activates lymphangiogenesis or new lymphatic vessel growth. It does this through binding to a cell membrane tyrosine kinase receptor, vascular endothelial growth factor receptor-3 (VEGFR-3), the activation of which is essential for the growth and development of new lymphatic vessels,' said the researchers. The team probed the therapeutic efficacy of VEGF-C in ameliorating gut lymphatic dysfunction and improving lymph drainage. Owing to the hydrophilicity, short half-life, and systemic side effects of VEGF-C, the team led by Dr Subham Banerjee from NIPER Guwahati first focused on the development of VEGF-C encapsulated reverse micelle-based nanocarriers, which specifically bind to VEGFR-3 homodimers. Next, the ILBS team, led by Dr Savneet Kaur, tested the developed VEGF-C nanocarriers extensively in animal models of advanced cirrhosis and portal hypertension. The developed molecule was delivered via the oral route to ensure its gut lymphatic vessel uptake in the animal models. The team showed that VEGF-C nanocarriers significantly increased mesenteric lymph drainage, which reduced ascites. Importantly, the treatment also led to an attenuation of the portal pressures, improved cytotoxic T-cell immunity in mesenteric lymph nodes, and reduced local and systemic bacterial load. The research, published in the JHEP Reports journal, is the first to highlight that therapeutic lymphangiogenesis with VEGF-C is a promising treatment for reconstructing the fragmented lymphatic network and restoring lymphatic function and drainage in advanced cirrhosis.
Yahoo
27-01-2025
- Business
- Yahoo
Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now?
We recently compiled a list of the . In this article, we are going to take a look at where Opthea Limited (NASDAQ:OPT) stands against other best Australian stocks to buy now. According to a report by Vanguard published on January 24, Australia's economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024. The report forecasts an economic growth of 2% year over year by the end of 2025, with trimmed mean inflation, a core measure that excludes items at the extremes, expected to reach 2.5% year over year. However, the report notes that low productivity growth and higher unit labor costs will keep core inflation from falling sustainably to the midpoint of the Reserve Bank of Australia's (RBA) 2%–3% target range until later in 2025. The RBA has left its policy rate target unchanged at 4.35% since December 10, but has softened its language around future policy decisions, noting that it is 'gaining some confidence that inflation is moving sustainably toward the target.' Despite this, Vanguard expects the RBA to remain patient and not initiate rate cuts until the second quarter of 2025, due to a tight labor market. READ ALSO: 12 Most Promising Green Stocks According to Hedge Funds and 10 Worst Performing Energy Stocks in 2024. In an interview on January 19, Lochlan Halloway, Market Strategist at Morningstar Australia, pointed out that the premium to fair value of large-cap stocks in the Australian market is abnormally high, trading at around 20% above fair value. According to Halloway, this is a concern as 20 companies account for about 60% of the ASX 100. In terms of value opportunities, Halloway identified the energy sector, particularly companies that are trading at significant discounts to their fair value. He also noted that small-cap companies, which were largely left behind in the market rally may offer value, although investors need to be judicious in selecting quality companies. Additionally, sectors such as consumer defensives appear close to fair value or even cheap. As the Australian economy gradually recovers in 2025, opportunities lie in undervalued sectors such as energy and consumer defensives, as well as among small-cap companies that have yet to catch up with the broader market rally. A researcher in a lab coat studying the effects of VEGFR-3 on vascular leakage. To compile our list of the 10 best Australian stocks to buy now, we used Finviz and Yahoo stock screeners to identify Australian companies. We then used Insider Monkey's Hedge Fund database to rank 10 stocks according to the largest number of hedge fund holders, as of Q3 2024. The list is sorted in ascending order of hedge fund sentiment. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here). Number of Hedge Fund Holdings: 3 Opthea Limited (NASDAQ:OPT) is a biotechnology company specializing in ophthalmology, developing treatments for eye diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema. The company works with ophthalmologists and healthcare organizations. Opthea Limited's (NASDAQ:OPT) lead candidate, sozinibercept, is a biologic designed to inhibit VEGF-C and VEGF-D, complementing the action of VEGF-A inhibitors. The company is conducting two pivotal Phase 3 studies, COAST and ShORe, which aim to evaluate the efficacy and safety of sozinibercept in combination with existing VEGF-A inhibitors, Eylea and Lucentis, respectively. These studies have enrolled nearly 2,000 treatment-naïve wet AMD patients across over 300 global sites. Topline results from the COAST and ShORe study are expected in mid-2025. While the wet AMD market is highly competitive, with established therapies such as Eylea, Vabysmo, and Lucentis dominating, Opthea Limited (NASDAQ:OPT) is positioning sozinibercept as a complementary therapy that can enhance the efficacy of current treatments. The company's strategy hinges on demonstrating that the additional benefit of targeting VEGF-C and VEGF-D can lead to better visual outcomes and improved patient quality of life. Overall OPT ranks 7th on our list of the best Australian stocks to buy now. While we acknowledge the potential of OPT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OPT but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at . Sign in to access your portfolio
